Actualités et Activités de Tris Pharma
Dirigeants
Voir l'organigramme avec ses 17 principaux dirigeants
Biographies les plus recherchées chez Tris Pharma
- Ketan Mehta, Chief Executive Officer and President
- Peter Ciano, Chief Financial Officer and Senior Vice President, C...
- Cheryl Patnick, Chief Administrative Officer
Changements de dirigeants chez Tris Pharma
- Manesh Naidu qui était Vice President, Marketing, est promu Chief Commercial Officer (publié le 17 septembre 2024).
Créer une alerte
pour suivre les mouvements de dirigeants chez Tris Pharma.
Pharmacie
Tris Pharma a 1 834 concurrents dont Pfizer (Etats—Unis), Sanofi (France) et Eli Lilly (Etats—Unis).
Actualités en fusion/acquisition en Pharmacie.
- Imbria Pharmaceuticals vient d'annoncer une levée de fonds de 58 millions de dollars. (publié le 10 avril 2025).
- Clario a acquis NRx Pharmaceuticals (publié le 18 mars 2025).
- Knight Therapeutics has announced the acquisition of Paladin Labs (publié le 12 mars 2025).
Contacts en Pharmacie
Actualités
Derniers communiqués de presse par Tris Pharma
- Media Highlights and Coverage | Tris Pharma
- Tris Pharma Launches Digital Health Business to Develop and Commercialize Digital Products for ADHD | Tris Pharma
- Tris Pharma Appoints Michael Magee as Vice President, Quality & Compliance | Tris Pharma
- Tris Pharma Appoints Franchesca Fowler to Chief Compliance Officer and Vice President, General Counsel | Tris Pharma
- Tris Pharma Partners with Perigon Pharmacy 360 to Enhance Access to DYANAVEL® XR Tablets for the Treatment of Attention Deficit Hyperactivity Disorder | Tris Pharma
- Tris Pharma Secures First ex-US Authorizations for Quillivant ER Oral Suspension and Quillivant ER Chewable Tablet for the Treatment of Attention Deficit Hyperactivity Disorder | Tris Pharma
- Tris Pharma Presents Data Reinforcing Limited Abuse Potential of Investigational Pain Therapy Cebranopadol at the 2023 PAINWeek Conference | Tris Pharma
- Tris Pharma Awarded Five-Year Grant of Up to $16.6M From the NIH's National Institute on Drug Abuse to Advance Cebranopadol for the Treatment of Opioid Use Disorder | Tris Pharma
- Tris Pharma Expands Leadership Team as Company Broadens Commercial Portfolio and Progresses Clinical Pipeline | Tris Pharma
- Tris Pharma Announces FDA Approval of DYANAVEL® XR (amphetamine) Once-Daily Extended-Release Oral Tablets, CII, for ADHD | Tris Pharma
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Tris Pharma
- Tris Pharma sur Wikipédia, Google News & Yahoo Finance en 1-click
- Tris Pharma sur LinkedIn, Twitter & YouTube en 1-click
